You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

  • Authors: Thomas Herzog, MD; Elizabeth M. Swisher, MD; Kristin K. Zorn, MD
  • CME Released: 5/6/2014
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 5/6/2015
Start Activity


Target Audience and Goal Statement

This activity is intended for oncologists, obstetricians/gynecologists, and other healthcare professionals who treat patients with ovarian cancer.

The goal of this activity is to discuss the emergence of poly (ADP-ribose) polymerase (PARP) inhibition for the treatment of ovarian cancer.

Upon completion of this activity, participants will be able to:

  1. Explain why PARP is essential for tumor growth and how use of PARP inhibitors may shrink tumors in BRCA1/BRCA2-mutated cancers
  2. Critically analyze data from clinical trials evaluating the safety and efficacy of PARP inhibitors in the treatment of BRCA-driven (BRCA1/BRCA2 mutations) ovarian cancer
  3. Select and apply appropriate testing to evaluate the molecular tumor profiles of patients with ovarian cancer and identify patients who may benefit from PARP inhibitor therapy


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Authors

  • Thomas Herzog, MD

    Physicians and Surgeons Alumni Professor, Clinical Gynecology and Obstetrics; Director, Division of Gynecologic Oncology, Columbia University Medical Center, New York, New York

    Disclosures

    Disclosure: Thomas Herzog, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Genentech, Inc.; Merck & Co., Inc.; Morphotek, Inc.

    Dr Herzog does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Herzog does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Elizabeth M. Swisher, MD

    Professor of Obstetrics and Gynecology, University of Washington School of Medicine; Medical Director, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, Seattle, Washington

    Disclosures

    Disclosure: Elizabeth M. Swisher, MD, has disclosed no relevant financial relationships.

    Dr Swisher does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Swisher does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Kristen K. Zorn, MD

    Associate Professor; Director, Division of Gynecologic Oncology; Director, Hereditary Gynecologic Cancer Clinic, University of Arkansas for Medical Sciences, Little Rock, Arkansas

    Disclosures

    Disclosure: Kristin K. Zorn, MD, has disclosed no relevant financial relationships.

    Dr Zorn does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Zorn does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Charlotte Warren

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

CME Reviewer

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Authors: Thomas Herzog, MD; Elizabeth M. Swisher, MD; Kristin K. Zorn, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 5/6/2014

Valid for credit through: 5/6/2015

processing....

This feature requires the newest version of Flash. You can download it here.